Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

It’s time to invest in Canada

This isn't the first time that I've written about Canada, a well-run country that has avoided many of the mistakes made by the United States. Its budget deficit is moderate, its balance-of-payments deficit is also small, its banking system is in pretty good shape and it face...
Martin Hutchinson | October 28, 2012 |

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. ...
Streetwise Reports | April 28, 2020 |

Gold versus fiat

What exactly does it mean when pundits say that gold is a “store of value” and “hedge against inflation”? In this article we’re diving deep into these questions and discussing how gold has performed over tim...
Richard (Rick) Mills | May 1, 2020 |

E-mini Dow Jones Industrial Average (YM) Futures Technical Analysis – Early Look Shows Market Holdin

The first short-term range is 28197 to 27312. Its 50% level or pivot at 27755 is support. It’s also controlling the near-term direction of the Dow. The range for the week is 28047 to 27726. Its 50% level is 27887. Aggressive traders may want to use this level ...
FX Empire | December 12, 2019 |

Grenke, JinkoSolar, Velocity Minerals - continue buying gold or are there alternatives?

Nowhere in the world, was more gold bought in the first six months of 2020 than in Germany. Coins and bars in the amount of about 83 tons went into the hands of the citizens. According to the World Gold Council, this represents an increase of 120% compared to the same period l...
Mario Hose | September 21, 2020 |

Fed Cut Equities Stimulus 86% This Week and Stocks Are Falling

What happens to the global markets when the US Fed begins to weaken stimulus activity and when the global markets must begin to function on their own? Are the global markets capable of sustaining current price levels without the Fed supporting them? A recent news article s...
Chris Vermeulen | May 1, 2020 |

A massive bull market is building for gold

Imagine, if you will, there was no coronavirus. No haz-mat suits, medical masks & gloves, no make-shift morgues. No terminally ill patients hooked up to ventilators, no horrible deaths without love ones close, no lockdowns, no social distancing, no deserted streets, no bailo...
Richard (Rick) Mills | April 17, 2020 |

Silver Offers A Golden Opportunity To Preserve Soon To Be Destroyed Value

The fundamentals for silver and gold are very strong, and with all the massive bailouts and stimulus, which have increased debt levels, they are just getting stronger. Until a significant portion of these debts is repaid or defaulted on, it would be foolish to talk about a to...
Hubert Moolman | July 3, 2020 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

AOL, Inc. (AOL): Can it fly in the face of skepticism?

Late last week, analysts at Macquarie launched coverage of AOL, Inc. ( NYSE: AOL , Stock Forum ) with a "neutral" rating and a $27 price target, essentially implying that they don't expect the stock to move much higher in the near future. Nevertheless, unenthusiastic ra...
Andrea Kramer | October 28, 2012 |
1 2 3 4 5 6 7 8 9 10 ...